Development of a minimal saponin vaccine adjuvant based on QS-21 - Wikidata - awgldk - TriplyDB

Development of a minimal saponin vaccine adjuvant based on QS-21

Development of a minimal saponin vaccine adjuvant based on QS-21

http://www.wikidata.org/entity/Q34433407

about

Development of Improved Vaccine Adjuvants Based on the Saponin Natural Product QS-21 through Chemical Synthesis A Functional Group Approach for Prediction of APPI Response of Organic Synthetic Targets.Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants.Potent response of QS-21 as a vaccine adjuvant in the skin when delivered with the Nanopatch, resulted in adjuvant dose sparing."Pruning of biomolecules and natural products (PBNP)": an innovative paradigm in drug discovery.Recent Developments in Synthetic Carbohydrate-Based Diagnostics, Vaccines, and Therapeutics.Carbohydrate-based vaccine adjuvants - discovery and development.Synthetic agonists of NOD-like, RIG-I-like, and C-type lectin receptors for probing the inflammatory immune response.Quillaja Saponin Variants with Central Glycosidic Linkage Modifications Exhibit Distinct Conformations and Adjuvant Activities Synthesis, Formulation, and Adjuvanticity of Monodesmosidic Saponins with Olenanolic Acid, Hederagenin and Gypsogenin Aglycones, and some C-28 Ester Derivatives.Versatile strategy for the divergent synthesis of linear oligosaccharide domain variants of Quillaja saponin vaccine adjuvants.Heterovalent Glycodendrimers as Epitope Carriers for Antitumor Synthetic Vaccines.Semisynthesis of Analogues of the Saponin Immunoadjuvant QS-21.Rapid assembly of the doubly-branched pentasaccharide domain of the immunoadjuvant jujuboside A via convergent B(C6F5)3-catalyzed glycosylation of sterically-hindered precursors.

P2860

Q28829361-479843C3-9FAF-4F6B-9D37-4D1D4A758349 Q33464842-B5EE4489-C9F4-470B-A5FB-BB0C17693F45 Q35539051-818C62F4-E7BB-499A-BB63-7A9B1338BE50 Q36466129-656DB0CC-0DFB-44D0-95DB-38FD23B85A9D Q37087055-FC6BA366-5264-48A6-A519-26E7E8EC2F85 Q38475630-FF0CFAEF-A4D2-46BC-B26B-42033FED6756 Q38533442-1A1B7331-A7F4-419C-9971-4A7D2CB496A2 Q38587300-A2AB2687-C38D-42F2-B463-EDD18FAA14F5 Q38646999-3096CF97-21F5-4DC1-A9DA-9C2A08926584 Q39236688-AC679EF6-5844-4405-BB97-07E47AD7EC37 Q41858914-67EEC994-E435-445B-A361-EF0881047F33 Q43178410-9F1B7779-7458-47EA-BA5D-9F4157231526 Q48169265-F97B1D56-3264-40BB-9A3A-D17A30009F20 Q49620985-DE70B54A-8475-40CC-B2BD-8465CE05E867 Q52652417-53C5983E-6EF6-4669-AFDD-BDA3C67BA11C

P2860

Development of a minimal saponin vaccine adjuvant based on QS-21

http://www.wikidata.org/entity/Q34433407

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Development of a minimal saponin vaccine adjuvant based on QS-21

@ast

Development of a minimal saponin vaccine adjuvant based on QS-21

@en

Development of a minimal saponin vaccine adjuvant based on QS-21

@nl

type

label

Development of a minimal saponin vaccine adjuvant based on QS-21

@ast

Development of a minimal saponin vaccine adjuvant based on QS-21

@en

Development of a minimal saponin vaccine adjuvant based on QS-21

@nl

prefLabel

Development of a minimal saponin vaccine adjuvant based on QS-21

@ast

Development of a minimal saponin vaccine adjuvant based on QS-21

@en

Development of a minimal saponin vaccine adjuvant based on QS-21

@nl

P1433

Q34433407-B4B9775A-4290-4516-B0E0-47DCE570ACFB

P1476

Q34433407-D6D0CA73-B04E-49BB-B1B0-6DDAE0A23116

P2093

Q34433407-1DF188A7-12A0-4354-9303-ACF8470859A4

Q34433407-5B660A48-4B44-42AF-A08D-74BCB2853339

Q34433407-625E67E7-3F81-44B6-9862-8EC8600D1359

Q34433407-719F64A5-89C7-4CAA-80F2-3BC64260AC8D

Q34433407-7B164530-DE07-406E-A23C-85D899EFBDE8

Q34433407-838C6E18-5FCE-4A33-8530-5A36FE1A73A1

Q34433407-98EF1191-0FD8-454A-B528-5D6187DF92EB

Q34433407-B7E305DD-FAE9-4614-83C7-2D38FCFC6C85

Q34433407-D0F04CDA-EEC1-47D6-BD68-DE4922A94149

Q34433407-D4A4603A-9B6E-42A2-8599-804D124FFE8D

P2860

Q34433407-0A5E9F81-6FAE-442B-91BA-37E01A0AAC10

Q34433407-1A833A3C-28A8-4EB0-938E-E34F0C259515

Q34433407-1CE91006-9DBA-4280-BC17-A0B4ABAB7935

Q34433407-40B92BA3-D2D0-4963-8B2C-F4795B08D412

Q34433407-41644290-1538-45A5-8B9A-30FEB68EEF76

Q34433407-5482FEF0-A8BE-461E-9942-02DB0B3F7095

Q34433407-5AE2B7E6-B998-475B-AFEA-926CB90A5711

Q34433407-6129A913-13E5-4E53-B769-1DDF3902AA62

Q34433407-6FADB75D-AF1A-477D-8291-FC2E7D9ACD9B

Q34433407-756249A4-B2CC-49A3-B33C-3D318A73D32B

P2888

Q34433407-3B4EFC63-57C5-4652-96EC-B657CA50A1F6

P304

Q34433407-06704CAA-34E9-41F4-9E9C-8F6DAFB8D5CF

P31

Q34433407-C648FA82-57FD-41CD-90E5-F32E50783CAC

P356

Q34433407-0A3046DF-D1D7-49B0-9172-1B3217A14041

P433

Q34433407-D4D4E347-96EE-4492-9E6F-81C13640667C

P478

Q34433407-0AFE8EFE-CCCA-412D-9E4B-595F327BCFC4

P577

Q34433407-735CC5A7-005E-4110-9556-C317EEEBF937

P5875

Q34433407-31A9076C-F650-4D96-928F-5AE431B04292

P6179

Q34433407-59FA0343-3780-42F4-8122-F6D005BD58AC

P698

Q34433407-26D31F3C-AFD6-4B84-8D66-4698E0F1B241

P932

Q34433407-67800501-F28D-4DF7-9853-8EF3789BA686

P356

P1433

Nature Chemistry

P1476

Development of a minimal saponin vaccine adjuvant based on QS-21

@en

P2093

Alberto Fernández-Tejada

http://www.w3.org/2001/XMLSchema#string

Constantine George

http://www.w3.org/2001/XMLSchema#string

David Y Gin

http://www.w3.org/2001/XMLSchema#string

Derek S Tan

http://www.w3.org/2001/XMLSchema#string

Eric K Chea

http://www.w3.org/2001/XMLSchema#string

Govind Ragupathi

http://www.w3.org/2001/XMLSchema#string

Jason S Lewis

http://www.w3.org/2001/XMLSchema#string

Jeffrey R Gardner

http://www.w3.org/2001/XMLSchema#string

NagaVaraKishore Pillarsetty

http://www.w3.org/2001/XMLSchema#string

Philip O Livingston

http://www.w3.org/2001/XMLSchema#string

P2860

Design and synthesis of potent Quillaja saponin vaccine adjuvants

Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders.

Unmet needs in modern vaccinology: adjuvants to improve the immune response.

ISCOMATRIX adjuvant combines immune activation with antigen delivery to dendritic cells in vivo leading to effective cross-priming of CD8+ T cells.

Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity.

Synthesis and preclinical evaluation of QS-21 variants leading to simplified vaccine adjuvants and mechanistic probes

Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer.

The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers

Synthesis of QS-21-xylose: establishment of the immunopotentiating activity of synthetic QS-21 adjuvant with a melanoma vaccine.

New horizons in adjuvants for vaccine development.

P2888

P304

635-643

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NCHEM.1963

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263394030

http://www.w3.org/2001/XMLSchema#string

P6179

1007891122

http://www.w3.org/2001/XMLSchema#string

P698

24950335

http://www.w3.org/2001/XMLSchema#string

P932

4215704

http://www.w3.org/2001/XMLSchema#string